NCT01817283 (CACTrip12) is a Phase 1/Phase 2 clinical trial of Triptolide in HIV, sponsored by LI Taisheng.

Who is sponsoring NCT01817283?

NCT01817283 is sponsored by LI Taisheng.

What drugs are being tested in NCT01817283?

Interventions in NCT01817283: Triptolide, cART, placebo.

Is NCT01817283 still recruiting?

NCT01817283 is currently status unknown. Last updated 22 March 2013.

Last reviewed 2013-03-22 · How we verify

NCT01817283: CACTrip12

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Triptolide Woldifiion T Cell Immune Activation and Inflammation Biomarkers in HIV-infected Immunological Non-responders

Status unknown Phase 1/Phase 2 Last updated 22 March 2013

What this trial tests

Phase 1/Phase 2 trial testing Triptolide in HIV in 150 participants. Status unknown.

Timeline

1 January 2013

Primary endpoint
1 July 2014

1 March 2015

Quick facts

Lead sponsor	LI Taisheng
Phase	Phase 1/Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	150
Start date	1 January 2013
Primary completion	1 July 2014
Estimated completion	1 March 2015
Sites	1 location across China

Drugs / interventions tested

Triptolide — full drug profile →
cART — full drug profile →
placebo

Conditions studied

HIV — all drugs for HIV →

Sponsor

LI Taisheng — full company profile →

Who can join

Adults 18 to 65, any sex, with HIV. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Changes of T cell immune activation and inflammation biomarkers
Time frame: baseline and at 4,8,12,24,36,48 weeks
T cell activation and inflammatory biomarkers including CD8+HLA-DR+/CD38+, IL-6, D-dimer and hsCRP,soluble CD14 and CD163, PD-1, CCR5 and CD57 should be measured at baseline and at Wee4, W12, W24, W36, W48 follow-up visits.

Sponsor's own description

This study is a prospective, multicenter, randomized, placebo-controlled clinical trial, to evaluate impact of Triptolide wilfordii on T cell immune activation and inflammation biomarkers in HIV-infected immunological non-responders.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

The potential of plant systems to break the HIV-TB link.
Habibi P, Daniell H, Soccol CR, Grossi-de-Sa MF. · · 2019 · cited 11× · PMID 30908823 · DOI 10.1111/pbi.13110
Triptolide-mediated immunomodulation of macrophages: from pathophysiology to therapy.
Chen Y, Zhu Q, Yin A, Wang W, et al · · 2025 · cited 2× · PMID 41144250 · DOI 10.1080/07853890.2025.2575302
Pleiotropic pharmacological activities and multiple-organ toxicities of triptolide: a programmed cell death perspective
Mao Y, Huang L, Long H, Huang Q, et al · · 2026

Verify or expand the search:

Other recruiting trials for HIV

Currently open trials in the same condition.

NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT07221214 — GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV · Phase 2 · recruiting
NCT07226128 — The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV · NA · recruiting
NCT07390474 — Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA i · Phase 1 · recruiting
NCT07390955 — A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1 · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01817283 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by LI Taisheng
Last refreshed: 22 March 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01817283.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing